| アブストラクト | BACKGROUND: Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries. METHODS: The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.S. health plan [US] and UK-Clinical Practice Research Datalink [CPRD GOLD]). This analysis included patients with newly diagnosed AD dementia in 2018-2019, who initiated symptomatic AD drug therapy, with >/= 1 year baseline period and >/= 1 year of follow-up. RESULTS: Over median follow-ups of 698 and 645 days, 63% and 65% of AD dementia patients used symptomatic treatments, with 34% and 77% newly initiating therapy, constituting analytic samples of 7637 patients in the US database and 4470 patients in the CPRD, respectively. The median time to the first therapy was 14 days for US and 49 days for CPRD; donepezil ranked the as most frequently used (69% vs 61%), followed by memantine (19% vs 28%) in the US database and CPRD, respectively. Median time on first therapy was 213 and 334 days, and 30% and 12% of patients proceeded to a second treatment in the US and CPRD databases, respectively. CONCLUSION: Approximately two thirds of newly diagnosed AD dementia patients utilized approved symptomatic treatment. Time on first therapy was relatively short (< 1 year) and the majority did not move to a second therapy, highlighting the need for better adherence and persistence to existing AD symptomatic therapies and the need for additional therapies to alleviate the significant burden of AD dementia. |
|---|
| ジャーナル名 | BMC neurology |
|---|
| Pubmed追加日 | 2023/11/10 |
|---|
| 投稿者 | DiBello, Julia R; Lu, Yifei; Swartz, Jina; Bortnichak, Edward A; Liaw, Kai-Li; Zhong, Wenjun; Liu, Xinyue |
|---|
| 組織名 | Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc.,;770 Sumneytown Pike, West Point, PA, 19486, USA.;Department of Epidemiology, Gillings School of Global Public Health, University;of North Carolina at Chapel Hill, Chapel Hill, NC, USA.;Exciva EXCIVA GmbH, Hauptstrasse 25, 69117, Heidelberg, Germany.;770 Sumneytown Pike, West Point, PA, 19486, USA. Xinyue.liu1@merck.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37946118/ |
|---|
